Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

abstract：:3-hydroxybenzo(a)pyrene (3-OHBaP) in urine has been proposed as a biomarker of occupational exposure to polycyclic aromatic hydrocarbons. However, to reconstruct exposure doses in workers from biomarker measurements, a thorough knowledge of the kinetics of the benzo(a)pyrene (BaP) and 3-OHBaP given different routes of...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Heredia-Ortiz R,Bouchard M

更新日期：2013-12-01 00:00:00

abstract：:This study developed an integrated model of severity scores of migraine headache and the incidence of nausea, photophobia, and phonophobia to predict the natural time course of migraine symptoms, which are likely to occur by a common disease progression mechanism. Data were acquired from two phase 3 clinical trials co...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Chae D,Park K

更新日期：2018-10-01 00:00:00

abstract：:The citalopram for Alzheimer's disease trial evaluated citalopram for the management for agitation in Alzheimer's disease patients. Sparse data was available from this elderly patient population. A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Akil A,Bies RR,Pollock BG,Avramopoulos D,Devanand DP,Mintzer JE,Porsteinsson AP,Schneider LS,Weintraub D,Yesavage J,Shade DM,Lyketsos CG

更新日期：2016-02-01 00:00:00

abstract：:Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Al-Huniti NH,Widness JA,Schmidt RL,Veng-Pedersen P

更新日期：2005-08-01 00:00:00

abstract：:HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

更新日期：2021-01-03 00:00:00

abstract：:Pharmacokinetic analysis in humans using compartmental models is restricted with respect to the estimation of parameter values. This is because the experimenter usually is only able to apply inputs and observations in a very small number of compartments in the system. This has implications for the structural identifia...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Cheung SY,Yates JW,Aarons L

更新日期：2013-02-01 00:00:00

abstract：:Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： dePillis LG,Eladdadi A,Radunskaya AE

更新日期：2014-10-01 00:00:00

abstract：:The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Gibiansky L,Gibiansky E

更新日期：2018-02-01 00:00:00

abstract：:Monoclonal antibodies (mAbs) represent a therapeutic strategy that has been increasingly used in different diseases. mAbs are highly specific for their targets leading to induce specific effector functions. Despite their therapeutic benefits, the presence of immunogenic reactions is of growing concern. The immunogenic...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Gómez-Mantilla JD,Trocóniz IF,Parra-Guillén Z,Garrido MJ

更新日期：2014-10-01 00:00:00

abstract：:A hazard model of fracture was developed using individual patient data (IPD) from the NHANES (2005-2008) database and summary-level data from an aggregate dataset (AD). The AD was built by performing a comprehensive and systematic literature search of clinical studies published from 1995 to 2015, recording fracture ra...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Eudy-Byrne RJ,Gillespie W,Riggs MM,Gastonguay MR

更新日期：2017-12-01 00:00:00

abstract：:A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Martinez JM,Khier S,Morita S,Rauch C,Fabre D

更新日期：2014-04-01 00:00:00

abstract：:There are situations in drug development where one may wish to reduce the dimensionality and complexity of whole body physiologically based pharmacokinetic models. A technique for formal reduction of such models, based on global sensitivity analysis, is suggested. Using this approach mean and variance of tissue(s) and...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Gueorguieva I,Nestorov IA,Rowland M

更新日期：2006-02-01 00:00:00

abstract：:Bioequivalence testing has been traditionally centered in summary variables such as AUC, C (max) and t (max) which filter out the intrinsic information conveyed by discrete sequential concentration-time observations. Comparing entire concentration-time profiles between test and reference formulations for bioequivalenc...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Pereira LM

更新日期：2007-08-01 00:00:00

abstract：:A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of PF-06804103 and T-DM1 was determined across a range of...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Betts A,Clark T,Jasper P,Tolsma J,van der Graaf PH,Graziani EI,Rosfjord E,Sung M,Ma D,Barletta F

更新日期：2020-10-01 00:00:00

abstract：:The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Claret L,Iliadis A,Macheras P

更新日期：2001-10-01 00:00:00

abstract：:Structural identifiability is an often overlooked, but essential, prerequisite to the experiment design stage. The application of structural identifiability analysis to models of myelosuppression is used to demonstrate the importance of its considerations. It is shown that, under certain assumptions, these models are ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Evans ND,Cheung SYA,Yates JWT

更新日期：2018-02-01 00:00:00

abstract：:The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rat...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Hing JP,Woolfrey SG,Greenslade D,Wright PM

更新日期：2001-04-01 00:00:00

abstract：:The aim of this study was to develop a population in vitro-in vivo pharmacokinetic model that simultaneously describe the absorption and accumulation kinetics of itraconazole (ICZ) and hydroxy-itraconazole (HICZ) in healthy subjects. The model integrated meta-models of gastrointestinal pH and gastrointestinal transit ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Abuhelwa AY,Mudge S,Upton RN,Foster DJR

更新日期：2018-04-01 00:00:00

abstract：:HbA1c is the most commonly used biomarker for the adequacy of glycemic management in diabetic patients and a surrogate endpoint for anti-diabetic drug approval. In spite of an empirical description for the relationship between average glucose (AG) and HbA1c concentrations, obtained from the A1c-derived average glucose...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Lledó-García R,Mazer NA,Karlsson MO

更新日期：2013-04-01 00:00:00

abstract：:Pegylated liposomal formulations contain lipid conjugated to polyethylene glycol. The disposition of encapsulated drug is dictated by the composition of the liposome, thus altering the pharmacokinetic (PK) profile of the drug. Allometric scaling is based on a power-log relationship between body weight (W) and drug cle...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Caron WP,Clewell H,Dedrick R,Ramanathan RK,Davis WL,Yu N,Tonda M,Schellens JH,Beijnen JH,Zamboni WC

更新日期：2011-10-01 00:00:00

abstract：:Development of novel therapies for bone diseases can benefit from mathematical models that predict drug effect on bone remodeling biomarkers. Therefore, a bone cycle model (BCM) was developed that takes into consideration the concept of the basic multicellular unit and the dynamic equilibrium of bone remodeling. The m...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： van Schaick E,Zheng J,Perez Ruixo JJ,Gieschke R,Jacqmin P

更新日期：2015-08-01 00:00:00

abstract：:A number of experimental observations in the late 1960s, early 1970s could not be explained by the pharmacokinetic theory available at that time. For example rats receiving phenobarbital as an enzyme inducing agent exhibited increased elimination of phenylbutazone in vitro in liver microsomes and in vivo in whole anim...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Benet LZ

更新日期：2010-12-01 00:00:00

abstract：:Mixture modeling within the context of pharmacokinetic (PK)/pharmacodynamic (PD) mixed effects modeling is a useful tool to explore a population for the presence of two or more subpopulations, not explained by evaluated covariates. At present, statistical tests for the existence of mixed populations have not been deve...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Frame B,Miller R,Lalonde RL

更新日期：2003-06-01 00:00:00

abstract：:We explore the use of fractional order differential equations for the analysis of datasets of various drug processes that present anomalous kinetics, i.e. kinetics that are non-exponential and are typically described by power-laws. A fractional differential equation corresponds to a differential equation with a deriva...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Dokoumetzidis A,Macheras P

更新日期：2009-04-01 00:00:00

abstract：:Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodynamic effects can occur, and be described using mathematical models; such a model informed approach can provide valuable ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Cheung SYA,Parkinson J,Wählby-Hamrén U,Dota CD,Kragh ÅM,Bergenholm L,Vik T,Collins T,Arfvidsson C,Pollard CE,Tomkinson HK,Hamrén B

更新日期：2018-06-01 00:00:00

abstract：:We explored the type I error rate (false positive rate) associated with exposure-response (ER) analyses for two compounds in a fixed-dose combination product through simulations. In the simulations, at least one compound was assumed to be inactive, whereas the active compound followed E(max) model at different concent...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Zhu H,Wang Y

更新日期：2011-12-01 00:00:00

abstract：:Mixture models are applied in population pharmacometrics to characterize underlying population distributions that are not adequately approximated by a single normal or lognormal distribution. In addition to obtaining individualized maximum a posteriori Bayesian post hoc parameter estimates, the subpopulation to which ...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Kaila N,Straka RJ,Brundage RC

更新日期：2007-04-01 00:00:00

abstract：:Bridging fundamental approaches to model optimization for pharmacometricians, systems pharmacologists and statisticians is a critical issue. These fields rely primarily on Maximum Likelihood and Extended Least Squares metrics with iterative estimation of parameters. Our research combines adaptive chaos synchronization...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Pillai N,Schwartz SL,Ho T,Dokoumetzidis A,Bies R,Freedman I

更新日期：2019-04-01 00:00:00

abstract：:During the course of therapeutic drug monitoring (TDM), doses are adjusted to attain a target concentration range and a correlation between clearance (CL) and dose is introduced. In population pharmacokinetic analyses of such TDM data, CL has frequently been modeled as a function of dose. This paper demonstrates by si...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Ahn JE,Birnbaum AK,Brundage RC

更新日期：2005-12-01 00:00:00

abstract：:The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the granulopoietic effects of Filgrastim in healthy volunteers was characterized via a population approach. Healthy male volunteers were enrolled into a four-way crossover clinical trial. Subjects received four single doses of Filgrastim (375 and 750 microgra...

journal_title：Journal of pharmacokinetics and pharmacodynamics

authors： Wang B,Ludden TM,Cheung EN,Schwab GG,Roskos LK

更新日期：2001-08-01 00:00:00